# US 2016/0251346 A1 · 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11 (beta)-hsd1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0251346 A1
- Document ID: US20160251346A1
- Status: Published application
- Kind: A1
- Application number: 15/154,254
- Filed: 2016-05-13
- Published: 2016-09-01
- Earliest claimed: 2010-04-29
- Assignees: The University of Edinburgh
- Applicants: The University Of Edinburgh
- Inventors: Scott Peter Webster; Jonathan Robert Seckl; Brian Robert Walker; Peter Ward; Thomas David Pallin; Hazel Joan Dyke; Trevor Robert Perrior
- Web page: https://patentgrep.com/patent/US20160251346A1

## CPC

- C07D 451/06: Oxygen atoms
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/08: for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/10: for osteoporosis
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/18: for HIV
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 409/14: containing three or more hetero rings
- C07D 451/02: containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D 451/04: with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone, 3,3-disubstituted-(6-aza-bicyclo[3.1.1]hept-6-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone, and 4,4-disubstituted piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds of the following formula that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

## Claims

### Claim at position 1

1-79. (canceled)

### Claim 80

A compound of the following formula, or a pharmaceutically acceptable salt thereof:
wherein:
-J1 and -J3 taken together form —CH2CH2—;
-Q is pyrid-2-yl and has n substituents —RF;
n is independently 0 or 1;
each —RF is independently —RZ, —F, —Cl, —CF3, —OH, —ORZ, —OCF3, —NH2, —NHRZZ, or —NRZZ2;
each —RZ is independently unsubstituted saturated aliphatic C1-4alkyl;
each —RZZ is independently saturated aliphatic C1-4alkyl;
—Y is independently —OH, —F, or —CN;
—RA1 is independently —H or —RAA;
—RA2 is independently —H or —RAA;
each —RAA is —RAA1;
each —RAA1 is independently unsubstituted saturated aliphatic C1-4alkyl;
—RB1 is independently —H or —RBB;
—RB2 is independently —H or —RBB;
each —RBB is —RBB1;
each —RBB1 is independently unsubstituted saturated aliphatic C1-4alkyl;
—RNN is independently —H or —RNN; and
each —RNN is independently saturated aliphatic C1-4alkyl.

### Claim 81 (depends on 80)

A compound according to claim 80, wherein —RA1 is —H; and —RA2 is —H.

### Claim 82 (depends on 80)

A compound according to claim 80, wherein —RB1 is —H; and —RB2 is —H.

### Claim 83 (depends on 81)

A compound according to claim 81, wherein —RB1 is —H; and —RB2 is —H.

### Claim 84 (depends on 80)

A compound according to claim 80, wherein —RN is —H.

### Claim 85 (depends on 81)

A compound according to claim 81, wherein —RN is —H.

### Claim 86 (depends on 82)

A compound according to claim 82, wherein —RN is —H.

### Claim 87 (depends on 83)

A compound according to claim 83, wherein —RN is —H.

### Claim 88 (depends on 80)

A compound according to claim 80, wherein each —RZ is -Me; and each —RZZ is -Me.

### Claim 89 (depends on 81)

A compound according to claim 81, wherein each —RZ is -Me; and each —RZZ is -Me.

### Claim 90 (depends on 82)

A compound according to claim 82, wherein each —RZ is -Me; and each —RZZ is -Me.

### Claim 91 (depends on 83)

A compound according to claim 83, wherein each —RZ is -Me; and each —RZZ is -Me.

### Claim 92 (depends on 84)

A compound according to claim 84, wherein each —RZ is -Me; and each —RZZ is -Me.

### Claim 93 (depends on 85)

A compound according to claim 85, wherein each —RZ is -Me; and each —RZZ is -Me.

### Claim 94 (depends on 86)

A compound according to claim 86, wherein each —RZ is -Me; and each —RZZ is -Me.

### Claim 95 (depends on 87)

A compound according to claim 87, wherein each —RZ is -Me; and each —RZZ is -Me.

### Claim 96 (depends on 80)

A compound according to claim 80, wherein n is 0.

### Claim 97 (depends on 81)

A compound according to claim 81, wherein n is 0.

### Claim 98 (depends on 82)

A compound according to claim 82, wherein n is 0.

### Claim 99 (depends on 83)

A compound according to claim 83, wherein n is 0.

### Claim 100 (depends on 84)

A compound according to claim 84, wherein n is 0.

### Claim 101 (depends on 85)

A compound according to claim 85, wherein n is 0.

### Claim 102 (depends on 86)

A compound according to claim 86, wherein n is 0.

### Claim 103 (depends on 87)

A compound according to claim 87, wherein n is 0.

### Claim 104 (depends on 80)

A compound according to claim 80, wherein Y is —OH.

### Claim 105 (depends on 87)

A compound according to claim 87, wherein Y is —OH.

### Claim 106 (depends on 95)

A compound according to claim 95, wherein Y is —OH.

### Claim 107 (depends on 103)

A compound according to claim 103, wherein Y is —OH.

### Claim 108 (depends on 80)

A compound according to claim 80, wherein Y is —F.

### Claim 109 (depends on 87)

A compound according to claim 87, wherein Y is —F.

### Claim 110 (depends on 95)

A compound according to claim 95, wherein Y is —F.

### Claim 111 (depends on 103)

A compound according to claim 103, wherein Y is —F.

### Claim 112 (depends on 80)

A compound according to claim 80, wherein Y is —CN.

### Claim 113 (depends on 87)

A compound according to claim 87, wherein Y is —CN.

### Claim 114 (depends on 95)

A compound according to claim 95, wherein Y is —CN.

### Claim 115 (depends on 103)

A compound according to claim 103, wherein Y is —CN.

### Claim 116 (depends on 106)

A compound according to claim 106, wherein —Y and the —CH2CH2— bridge are positioned on the same face of the piperidine ring.

### Claim 117 (depends on 107)

A compound according to claim 107, wherein —Y and the —CH2CH2— bridge are positioned on the same face of the piperidine ring.

### Claim 118 (depends on 110)

A compound according to claim 110, wherein —Y and the —CH2CH2— bridge are positioned on the same face of the piperidine ring.

### Claim 119 (depends on 111)

A compound according to claim 111, wherein —Y and the —CH2CH2— bridge are positioned on the same face of the piperidine ring.

### Claim 120 (depends on 114)

A compound according to claim 114, wherein —Y and the —CH2CH2— bridge are positioned on the same face of the piperidine ring.

### Claim 121 (depends on 115)

A compound according to claim 115, wherein —Y and the —CH2CH2— bridge are positioned on the same face of the piperidine ring.

### Claim 122 (depends on 106)

A compound according to claim 106, wherein —Y and the —CH2CH2— bridge are positioned on opposite faces of the piperidine ring.

### Claim 123 (depends on 107)

A compound according to claim 107, wherein —Y and the —CH2CH2— bridge are positioned on opposite faces of the piperidine ring.

### Claim 124 (depends on 110)

A compound according to claim 110, wherein —Y and the —CH2CH2— bridge are positioned on opposite faces of the piperidine ring.

### Claim 125 (depends on 111)

A compound according to claim 111, wherein —Y and the —CH2CH2— bridge are positioned on opposite faces of the piperidine ring.

### Claim 126 (depends on 114)

A compound according to claim 114, wherein —Y and the —CH2CH2— bridge are positioned on opposite faces of the piperidine ring.

### Claim 127 (depends on 115)

A compound according to claim 115, wherein —Y and the —CH2CH2— bridge are positioned on opposite faces of the piperidine ring.

### Claim 128 (depends on 80)

A pharmaceutical composition comprising a compound according to claim 80 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

### Claim 129 (depends on 80)

A method of preparing a pharmaceutical composition comprising the step of admixing a compound according to claim 80 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
